110 related articles for article (PubMed ID: 24984002)
1. Plk1 phosphorylation of IRS2 prevents premature mitotic exit via AKT inactivation.
Chen L; Li Z; Ahmad N; Liu X
Biochemistry; 2015 Apr; 54(15):2473-80. PubMed ID: 25830382
[TBL] [Abstract][Full Text] [Related]
2. Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties.
Bhuvanalakshmi G; Arfuso F; Millward M; Dharmarajan A; Warrier S
PLoS One; 2015; 10(6):e0127517. PubMed ID: 26030909
[TBL] [Abstract][Full Text] [Related]
3. CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas.
Gleize V; Alentorn A; Connen de Kérillis L; Labussière M; Nadaradjane AA; Mundwiller E; Ottolenghi C; Mangesius S; Rahimian A; Ducray F; ; Mokhtari K; Villa C; Sanson M
Ann Neurol; 2015 Sep; 78(3):355-74. PubMed ID: 26017892
[TBL] [Abstract][Full Text] [Related]
4. Upfront chemotherapy and subsequent resection for molecularly defined gliomas.
Sasaki H; Hirose Y; Yazaki T; Kitamura Y; Katayama M; Kimura T; Fujiwara H; Toda M; Ohira T; Yoshida K
J Neurooncol; 2015 Aug; 124(1):127-35. PubMed ID: 26007163
[TBL] [Abstract][Full Text] [Related]
5. Identification of therapeutic targets for glioblastoma by network analysis.
Friedmann-Morvinski D; Bhargava V; Gupta S; Verma IM; Subramaniam S
Oncogene; 2016 Feb; 35(5):608-20. PubMed ID: 25961929
[TBL] [Abstract][Full Text] [Related]
6. Molecular targets in glioblastoma.
Zorzan M; Giordan E; Redaelli M; Caretta A; Mucignat-Caretta C
Future Oncol; 2015; 11(9):1407-20. PubMed ID: 25952786
[TBL] [Abstract][Full Text] [Related]
7. Oligodendroglioma: pathology, molecular mechanisms and markers.
Wesseling P; van den Bent M; Perry A
Acta Neuropathol; 2015 Jun; 129(6):809-27. PubMed ID: 25943885
[TBL] [Abstract][Full Text] [Related]
8. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.
Turner KM; Sun Y; Ji P; Granberg KJ; Bernard B; Hu L; Cogdell DE; Zhou X; Yli-Harja O; Nykter M; Shmulevich I; Yung WK; Fuller GN; Zhang W
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3421-6. PubMed ID: 25737557
[TBL] [Abstract][Full Text] [Related]
9. Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma.
Ozawa T; Riester M; Cheng YK; Huse JT; Squatrito M; Helmy K; Charles N; Michor F; Holland EC
Cancer Cell; 2014 Aug; 26(2):288-300. PubMed ID: 25117714
[TBL] [Abstract][Full Text] [Related]
10. Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma.
Vengoji R; Atri P; Macha MA; Seshacharyulu P; Perumal N; Mallya K; Liu Y; Smith LM; Rachagani S; Mahapatra S; Ponnusamy MP; Jain M; Batra SK; Shonka N
J Exp Clin Cancer Res; 2021 Oct; 40(1):335. PubMed ID: 34696786
[TBL] [Abstract][Full Text] [Related]
11.
Wu L; Bernal GM; Cahill KE; Pytel P; Fitzpatrick CA; Mashek H; Weichselbaum RR; Yamini B
Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973405
[TBL] [Abstract][Full Text] [Related]
12. Increased infiltration and tolerised antigen-specific CD8
Bahador M; Gras Navarro A; Rahman MA; Dominguez-Valentin M; Sarowar S; Ulvestad E; Njølstad G; Lie SA; Kristoffersen EK; Bratland E; Chekenya M
Oncoimmunology; 2017; 6(8):e1336272. PubMed ID: 28919997
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.
Szopa W; Burley TA; Kramer-Marek G; Kaspera W
Biomed Res Int; 2017; 2017():8013575. PubMed ID: 28316990
[TBL] [Abstract][Full Text] [Related]
14. Lumbar puncture-administered resveratrol inhibits STAT3 activation, enhancing autophagy and apoptosis in orthotopic rat glioblastomas.
Xue S; Xiao-Hong S; Lin S; Jie B; Li-Li W; Jia-Yao G; Shun S; Pei-Nan L; Mo-Li W; Qian W; Xiao-Yan C; Qing-You K; Peng Z; Hong L; Jia L
Oncotarget; 2016 Nov; 7(46):75790-75799. PubMed ID: 27716625
[TBL] [Abstract][Full Text] [Related]
15. The role of AKT isoforms in glioblastoma: AKT3 delays tumor progression.
Joy A; Kapoor M; Georges J; Butler L; Chang Y; Li C; Crouch A; Smirnov I; Nakada M; Hepler J; Marty M; Feuerstein BG
J Neurooncol; 2016 Oct; 130(1):43-52. PubMed ID: 27422127
[TBL] [Abstract][Full Text] [Related]
16. Survival kinase genes present prognostic significance in glioblastoma.
Varghese RT; Liang Y; Guan T; Franck CT; Kelly DF; Sheng Z
Oncotarget; 2016 Apr; 7(15):20140-51. PubMed ID: 26956052
[TBL] [Abstract][Full Text] [Related]
17. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Kast RE; Karpel-Massler G; Halatsch ME
Oncotarget; 2014 Sep; 5(18):8052-82. PubMed ID: 25211298
[TBL] [Abstract][Full Text] [Related]
18. AKT pathway genes define 5 prognostic subgroups in glioblastoma.
Joy A; Ramesh A; Smirnov I; Reiser M; Misra A; Shapiro WR; Mills GB; Kim S; Feuerstein BG
PLoS One; 2014; 9(7):e100827. PubMed ID: 24984002
[TBL] [Abstract][Full Text] [Related]
19. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
